Trial Profile
A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary) ; Aldesleukin; Peginterferon alfa-2b
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Apr 2015 Status changed from recruiting to discontinued, as reported by European Clinical Trials Database record.
- 14 Oct 2013 New trial record